Himabindu Vidula, MD
Cardiovascular Disease · Rochester, NYNPI 1679736789
Payments from drug & device makers
Across 145 payments — averaging $1198.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$128K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$39K
- Alnylam Pharmaceuticals Inc.$6K
- Cvrx, Inc.$317
- Lilly USA, LLC$15
What the payments were for
- Consulting fees$22,47054%
- Travel & lodging$14,03234%
- Food & beverage$5,11612%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 123 | $127,981 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $39,071 |
| Alnylam Pharmaceuticals Inc. | 11 | $6,364 |
| Cvrx, Inc. | 4 | $317 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$19,513
- Tricuspid Valve Repair System$8,403
- ONPATTRO$6,173
- CARDIOMEMS$3,125
- CardioMEMS HF System$709
- HeartMate 3 Left Ventricular Assist Device$366
- Barostim Neo System$164
- HeartMate 3 Left Ventricular Dev$138
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$134
- HeartMate Touch$107
How this compares
$173,748 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 52 | $56,473 |
| JardianceEmpagliflozin | 22 | $24,942 |
| FarxigaDapagliflozin Propanediol | 18 | $18,408 |
| OzempicSemaglutide | 19 | $17,562 |
| Sildenafil Citrate | 20 | $10,240 |
| Bumetanide | 35 | $2,220 |
| Potassium Chloride | 53 | $1,565 |
| Torsemide | 30 | $885 |
| Warfarin Sodium | 50 | $769 |
| Amiodarone Hcl | 38 | $709 |
| Atorvastatin Calcium | 44 | $683 |
| Metoprolol Succinate | 34 | $626 |
| Lansoprazole | 18 | $611 |
| Carvedilol | 35 | $552 |
| Valsartan | 30 | $515 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- James EichelbergerRochester$332K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.